Useful for screening for the presence of IgM-class antibodies to Zika virus in symptomatic individuals, particularly symptomatic pregnant women, with either travel to a Zika virus endemic region or who have had sexual exposure to an individual with Zika virus.
Serum
SST (1)
None
Red (1)
Use for patients whose symptoms began, or whose documented exposure occurred, at least 14 days prior to testing.